Related Experiment Video
Updated: May 28, 2026
08:49
Models of Bone Metastasis
Published on: September 4, 2012
Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines
Shahid Qamar1, C Alex Carrasquer, Suzanne L Cunningham
1James Graham Brown Cancer Center, 529 South Jackson Street, University of Louisville, Louisville, KY 40202, U.S.A.
Anticancer Research
|October 4, 2011
Summary
The categorical structure-activity relationship (cat-SAR) program identified specific chemical features driving differential activity in breast cancer cell lines. This approach aids in discovering targeted anti-cancer agents with improved specificity.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Cancer Research
Background:
- The National Cancer Institute's Developmental Therapeutics Program (DTP) database contains screening results for approximately 43,000 compounds across 60 cancer cell lines.
- Identifying compounds with selective activity against specific cancer cell lines is crucial for developing targeted therapies.
Purpose of the Study:
- To apply the categorical structure-activity relationship (cat-SAR) program to identify structural attributes of compounds with differential cytostatic or cytotoxic activity between breast cancer cell lines.
- To distinguish features responsible for broad antiproliferative activity from those specific to a particular cell type.
Main Methods:
- Developed SAR models for cytostatic and cytotoxic activity against MCF-7 and MDA-MB-231 breast cancer cell lines.
- Created differential activity models focusing on compounds potent in one cell line but not the other, and those equally potent.
- Utilized leave-one-out cross-validation for model assessment.
Main Results:
- Individual MCF-7 and MDA-MB-231 models achieved 83-85% concordance.
- Differential activity models showed 66-76% concordance.
- The cat-SAR approach successfully identified chemical attributes linked to selective activity in MCF-7 and MDA-MB-231 cells.
Conclusions:
- The cat-SAR approach effectively identified cell line-specific activity drivers for breast cancer.
- This methodology can facilitate the discovery of highly specific anti-breast cancer agents.
- The approach holds potential for developing SAR models that identify compounds targeting specific cancer types while sparing others.
